<DOC>
	<DOCNO>NCT02006706</DOCNO>
	<brief_summary>This study evaluate efficacy safety MabThera/Rituxan plus methotrexate patient active rheumatoid arthritis inadequate response least 1 DMARD treatment . All patient receive MabThera ( 1000mg iv infusion ) day 1 15 , methotrexate ( 10-25mg po ) weekly . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study MabThera/Rituxan ( Rituximab ) Combination With Methotrexate Patients With Rheumatoid Arthritis Inadequate Response DMARD Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>adult patient , 1880 year age ; rheumatoid arthritis inadequate response &gt; =1 DMARD treatment ; active disease ; DMARDs methotrexate withdrawn least 4 week prior start study treatment . autoimmune disease rheumatoid arthritis ; bone/joint surgery within 8 week prior screen , joint surgery plan within 24 week MabThera infusion ; concurrent treatment DMARD antiTNFalfa ; intraarticular parenteral corticosteroid within 4 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>